遗传性血管性水肿治疗方式与疾病负担研究进展

doi:10.35541/cjd.20220205

中华皮肤科杂志 ›› 2024, e20220205.doi: 10.35541/cjd.20220205

• 综述 • 下一篇

遗传性血管性水肿治疗方式与疾病负担研究进展

刘佳^1，2 谷映桦^1，2 贺小宁^1，2

¹天津大学药物科学与技术学院，天津 300072；²天津大学社会科学调查与数据中心，天津 300072

收稿日期:2022-03-29 修回日期:2023-03-27 发布日期:2024-03-11
通讯作者: 贺小宁 E-mail:hexn@tju.edu.cn

Treatment and disease burden of hereditary angioedema

Liu Jia^1,2, Gu Yinghua^1,2, He Xiaoning^1,2

¹School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China; ²Center for Social Survey and Data, Tianjin University, Tianjin 300072, China

Received:2022-03-29 Revised:2023-03-27 Published:2024-03-11
Contact: He Xiaoning E-mail:hexn@tju.edu.cn

摘要/Abstract

摘要： 【摘要】遗传性血管性水肿（HAE）是一种常染色体显性遗传病，主要表现为皮肤和黏膜水肿，其全球患病率约为1/50 000，我国目前尚缺乏相关流行病学数据。作为一种罕见病，HAE在临床和社会中的认知度至今仍然很低，因此常被误诊、误治，严重影响患者的生活质量和寿命，为家庭和社会带来沉重的经济负担。本研究对HAE的流行病学、治疗方式、患者经济负担以及患者健康相关生命质量进行梳理与总结，旨在促进临床医生及医疗卫生决策者充分认识HAE。

关键词: 血管水肿, 遗传性, 患病代价, 治疗, 生活质量

Abstract: 【Abstract】 Hereditary angioedema （HAE） is an autosomal dominant genetic disease characterized by swelling of the skin and mucosa. The global prevalence of HAE is about 1/50 000, but relevant epidemiological data are still lacking in China. As a rare disease, HAE is still poorly recognized in clinical practice and society, often leading to misdiagnosis and incorrect treatment. Moreover, it seriously affects the quality of life and lifespan of patients, and brings a heavy economic burden to families and society. This review summarizes the epidemiology, treatment strategies, economic burden of HAE, as well as health-related quality of life of patients, aiming to improve the understanding of HAE among clinicians and healthcare decision-makers.

Key words: Angioedemas, hereditary, Cost of illness, Therapy, Quality of life

刘佳谷映桦贺小宁. 遗传性血管性水肿治疗方式与疾病负担研究进展[J]. 中华皮肤科杂志, 2024,e20220205. doi:10.35541/cjd.20220205

Liu Jia, Gu Yinghua, He Xiaoning, . Treatment and disease burden of hereditary angioedema[J]. Chinese Journal of Dermatology,2024,e20220205. doi:10.35541/cjd.20220205

参考文献 47

［1］	Giavina⁃Bianchi P, Arruda LK, Aun MV, et al. Brazilian guidelines for hereditary angioedema management ⁃ 2017 update part 1: definition, classification and diagnosis［J］. Clinics（Sao Paulo）, 2018,73:e310. doi: 10.6061/clinics/2018/e310.
［2］	Cicardi M, Aberer W, Banerji A, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group［J］. Allergy, 2014,69（5）:602⁃616. doi: 10.1111/all.12380.
［3］	Maurer M, Magerl M, Ansotegui I, et al. The international WAO/EAACI guideline for the management of hereditary angioedema⁃The 2017 revision and update［J］. Allergy, 2018,73（8）:1575⁃1596. doi: 10.1111/all.13384.
［4］	Schöffl C, Wiednig M, Koch L, et al. Hereditary angioedema in Austria: prevalence and regional peculiarities［J］. J Dtsch Dermatol Ges, 2019,17（4）:416⁃423. doi: 10.1111/ddg.13815.
［5］	曹阳, 刘爽, 支玉香. 遗传性血管性水肿发病机制研究进展［J］. 中国医学科学院学报, 2020,42（5）:686⁃690. doi: 10.3881/j.issn.1000⁃503X.11407.
［6］	Longhurst HJ, Dempster J, Lorenzo L, et al. Real⁃world outcomes in hereditary angioedema: first experience from the Icatibant Outcome Survey in the United Kingdom［J］. Allergy Asthma Clin Immunol, 2018,14:28. doi: 10.1186/s13223⁃018⁃0253⁃x.
［7］	Henao MP, Kraschnewski JL, Kelbel T, et al. Diagnosis and screening of patients with hereditary angioedema in primary care［J］. Ther Clin Risk Manag, 2016,12:701⁃711. doi: 10.2147/TCRM.S86293.
［8］	Gabos G, Nadasan V, Mihaly E, et al. Hereditary angioedema due to C1⁃inhibitor deficiency in Romania: first national study, diagnostic and treatment challenges［J］. Iran J Immunol, 2020,17（3）:226⁃235. doi: 10.22034/iji.2020.85416.1709.
［9］	Bewtra AK, Levy RJ, Jacobson KW, et al. C1⁃inhibitor therapy for hereditary angioedema attacks: prospective patient assessments of health⁃related quality of life［J］. Allergy Asthma Proc, 2012,33（5）:427⁃431. doi: 10.2500/aap.2012.33.3597.
［10］	Xu YY, Zhi YX, Liu RL, et al. Upper airway edema in 43 patients with hereditary angioedema［J］. Ann Allergy Asthma Immunol, 2014,112（6）:539⁃544.e1. doi: 10.1016/j.anai.2014.03. 003.
［11］	Ayazi M, Fazlollahi MR, Mohammadzadeh I, et al. Delayed diagnosis of hereditary angioedema with C1⁃inhibitor deficiency in iranian children and adolescents［J］. Pediatr Allergy Immunol, 2019,30（3）:395⁃398. doi: 10.1111/pai.13028.
［12］	Zanichelli A, Longhurst HJ, Maurer M, et al. Misdiagnosis trends in patients with hereditary angioedema from the real⁃world clinical setting［J］. Ann Allergy Asthma Immunol, 2016,117（4）:394⁃398. doi: 10.1016/j.anai.2016.08.014.
［13］	国家卫生健康委办公厅.国家卫生健康委办公厅关于印发罕见病诊疗指南（2019年版）的通知（EB/OL）.（2019⁃02⁃27）［2021⁃08⁃31］. http://www.nhc.gov.cn/yzygj/s7659/201902/61d06b 4916c348e0810ce1fceb844333.shtml.
［14］	Roche O, Blanch A, Caballero T, et al. Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain［J］. Ann Allergy Asthma Immunol, 2005,94（4）:498⁃503. doi: 10.1016/S1081⁃1206（10）61121⁃0.
［15］	Gompels MM, Lock RJ, Abinun M, et al. C1 inhibitor deficiency: consensus document［J］. Clin Exp Immunol, 2005,139（3）:379⁃394. doi: 10.1111/j.1365⁃2249.2005.02726.x.
［16］	Bygum A. Hereditary angio⁃oedema in Denmark: a nationwide survey［J］. Br J Dermatol, 2009,161（5）:1153⁃1158. doi: 10. 1111/j.1365⁃2133.2009.09366.x.
［17］	Zanichelli A, Arcoleo F, Barca MP, et al. A nationwide survey of hereditary angioedema due to C1 inhibitor deficiency in Italy［J］. Orphanet J Rare Dis, 2015,10:11. doi: 10.1186/s13023⁃015⁃0233⁃x.
［18］	Jung JW, Suh DI, Park HJ, et al. Clinical features of hereditary angioedema in Korean patients: a nationwide multicenter study［J］. Int Arch Allergy Immunol, 2018,176（3⁃4）:272⁃279. doi: 10.1159/000488350.
［19］	Bouillet L, Launay D, Fain O, et al. Hereditary angioedema with C1 inhibitor deficiency: clinical presentation and quality of life of 193 French patients［J］. Ann Allergy Asthma Immunol, 2013,111（4）:290⁃294. doi: 10.1016/j.anai.2013.07.012.
［20］	Blasco AJ, Lázaro P, Caballero T, et al. Social costs of icatibant self⁃administration vs. health professional⁃administration in the treatment of hereditary angioedema in Spain［J］. Health Econ Rev, 2013,3（1）:2. doi: 10.1186/2191⁃1991⁃3⁃2.
［21］	Federici C, Perego F, Borsoi L, et al. Costs and effects of on⁃demand treatment of hereditary angioedema in Italy: a prospective cohort study of 167 patients［J］. BMJ Open, 2018,8（7）:e022291. doi: 10.1136/bmjopen⁃2018⁃022291.
［22］	Lumry WR. Hereditary angioedema: the economics of treatment of an orphan disease［J］. Front Med（Lausanne）, 2018,5:22. doi: 10.3389/fmed.2018.00022.
［23］	Busse PJ, Christiansen SC, Birmingham JM, et al. Development of a health⁃related quality of life instrument for patients with hereditary angioedema living in the United States［J］. J Allergy Clin Immunol Pract, 2019,7（5）:1679⁃1683.e7. doi: 10.1016/j.jaip.2018.11.042.
［24］	Bernstein JA, Tyson C, Relan A, et al. Modeling cost⁃effectiveness of on⁃demand treatment for hereditary angioedema attacks［J］. J Manag Care Spec Pharm, 2020,26（2）:203⁃210. doi: 10.18553/jmcp.2019.19217.
［25］	Mendivil J, Murphy R, de la Cruz M, et al. Clinical characteristics and burden of illness in patients with hereditary angioedema: findings from a multinational patient survey［J］. Orphanet J Rare Dis, 2021,16（1）:94. doi: 10.1186/s13023⁃021⁃01717⁃4.
［26］	Xu YY, Jiang Y, Zhi YX, et al. Clinical features of hereditary angioedema in Chinese patients: new findings and differences from other populations［J］. Eur J Dermatol, 2013,23（4）:500⁃504. doi: 10.1684/ejd.2013.2105.
［27］	Bork K, Siedlecki K, Bosch S, et al. Asphyxiation by laryngeal edema in patients with hereditary angioedema［J］. Mayo Clin Proc, 2000,75（4）:349⁃354. doi: 10.4065/75.4.349.
［28］	Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1⁃INH deficiency［J］. J Allergy Clin Immunol, 2012,130（3）:692⁃697. doi: 10.1016/j.jaci.2012.05.055.
［29］	Cao Y, Liu S, Zhi Y. The natural course of hereditary angioedema in a Chinese cohort［J］. Orphanet J Rare Dis, 2020,15（1）:257. doi: 10.1186/s13023⁃020⁃01526⁃1.
［30］	Lunn ML, Santos CB, Craig TJ. Is there a need for clinical guidelines in the United States for the diagnosis of hereditary angioedema and the screening of family members of affected patients?［J］. Ann Allergy Asthma Immunol, 2010,104（3）:211⁃214. doi: 10.1016/j.anai.2009.12.004.
［31］	Zanichelli A, Magerl M, Longhurst H, et al. Hereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe［J］. Allergy Asthma Clin Immunol, 2013,9（1）:29. doi: 10.1186/1710⁃1492⁃9⁃29.
［32］	Grumach AS, Longhurst HJ, Aberer W, et al. Pediatricians diagnosed few patients with childhood⁃presented hereditary angioedema: Icatibant Outcome Survey findings［J］. J Allergy Clin Immunol Pract, 2019,7（3）:1078⁃1080. doi: 10.1016/j.jaip. 2018.07.047.
［33］	Betschel S, Badiou J, Binkley K, et al. The International/Canadian Hereditary Angioedema Guideline［J］. Allergy Asthma Clin Immunol, 2019,15:72. doi: 10.1186/s13223⁃019⁃0376⁃8.
［34］	Caballero T, Farkas H, Bouillet L, et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency［J］. J Allergy Clin Immunol, 2012,129（2）:308⁃320. doi: 10.1016/j.jaci.2011.11.025.
［35］	Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 Guidelines for the management of hereditary angioedema［J］. J Allergy Clin Immunol Pract, 2021,9（1）:132⁃150.e3. doi: 10.1016/j.jaip.2020.08.046.
［36］	Horiuchi T, Ohi H, Ohsawa I, et al. Guideline for hereditary angioedema（HAE） 2010 by the Japanese Association for Complement Research ⁃ secondary publication［J］. Allergol Int, 2012,61（4）:559⁃562. doi: 10.2332/allergolint.12⁃RAI⁃0471.
［37］	中华医学会变态反应学分会, 中国医师协会变态反应医师分会, 支玉香, 等. 遗传性血管性水肿的诊断和治疗专家共识［J］. 中华临床免疫和变态反应杂志, 2019,13（1）:1⁃4. doi: 10. 3969j.issn.1673⁃8705.2019.01.001.
［38］	Horiuchi T. Guideline for hereditary angioedema（HAE） 2010 by the Japanese Association for Complement Research: points for diagnosis and treatment［J］. Arerugi, 2014,63（6）:749⁃753.
［39］	张凌凡, 赵宇晗, 李智慧, 等. 遗传性血管性水肿治疗药物的临床研究进展［J］. 世界临床药物, 2020,41（4）:319⁃322. doi: 10.13683/j.wph.2020.04.015.
［40］	Wilson DA, Bork K, Shea EP, et al. Economic costs associated with acute attacks and long⁃term management of hereditary angioedema［J］. Ann Allergy Asthma Immunol, 2010,104（4）:314⁃320. doi: 10.1016/j.anai.2010.01.024.
［41］	Petraroli A, Squeglia V, Di Paola N, et al. Home therapy with plasma⁃derived C1 inhibitor: a strategy to improve clinical outcomes and costs in hereditary angioedema［J］. Int Arch Allergy Immunol, 2015,166（4）:259⁃266. doi: 10.1159/000381341.
［42］	Javaud N, Bouillet L, Rabetrano H, et al. Hereditary angioedema: clinical presentation and socioeconomic cost of 200 French patients［J］. J Allergy Clin Immunol Pract, 2019,7（1）:328⁃330. doi: 10.1016/j.jaip.2018.05.036.
［43］	Spanò R, Di Paola N, Bova M, et al. Value co⁃creation in healthcare: evidence from innovative therapeutic alternatives for hereditary angioedema［J］. BMC Health Serv Res, 2018,18（1）:571. doi: 10.1186/s12913⁃018⁃3389⁃y.
［44］	Castaldo AJ, Jervelund C, Corcoran D, et al. Assessing the cost and quality⁃of⁃life impact of on⁃demand⁃only medications for adults with hereditary angioedema［J］. Allergy Asthma Proc, 2021,42（2）:108⁃117. doi: 10.2500/aap.2021.42.200127.
［45］	Liu S, Wang X, Xu Y, et al. Health⁃related quality of life and its risk factors in Chinese hereditary angioedema patients［J］. Orphanet J Rare Dis, 2019,14（1）:191. doi: 10.1186/s13023⁃019⁃1159⁃5.
［46］	Aygören⁃Pürsün E, Bygum A, Beusterien K, et al. Estimation of EuroQol 5⁃Dimensions health status utility values in hereditary angioedema［J］. Patient Prefer Adherence, 2016,10:1699⁃1707. doi: 10.2147/PPA.S100383.
［47］	Engel⁃Yeger B, Farkas H, Kivity S, et al. Health⁃related quality of life among children with hereditary angioedema［J］. Pediatr Allergy Immunol, 2017,28（4）:370⁃376. doi: 10.1111/pai.12712.

[1]	《乳房外Paget病诊治专家共识（版）》编写委员会专家组. [开放获取] 乳房外Paget病诊治专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(5): 400-408.
[2]	中国医师协会皮肤科医师分会. [开放获取] 慢性瘙痒管理指南（2024版）[J]. 中华皮肤科杂志, 2024, 57(5): 387-399.
[3]	中国“一带一路”皮肤病专病联盟分枝杆菌病研究联盟中国麻风防治协会皮肤性病检验与诊断分会. [开放获取] 中国皮肤结核临床诊疗专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(5): 426-434.
[4]	中国医师协会皮肤科医师分会中国中西医结合学会皮肤性病学分会. 红皮病型银屑病诊疗中国专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(5): 409-417.
[5]	中国中西医结合学会皮肤性病学分会真菌学组中国耐药皮肤癣菌病诊治与防控工作组. 中国耐药皮肤癣菌感染诊治与防控专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(5): 418-425.
[6]	侯晓媛吴南辉徐明圆刘业强. JAK抑制剂巴瑞替尼治疗环状肉芽肿1例[J]. 中华皮肤科杂志, 2024, 57(5): 461-462.
[7]	严汝帆廖洁月郭子瑜姚南周文玉罗帅寒天张桂英赵明. 天疱疮发病机制和靶向治疗的研究进展[J]. 中华皮肤科杂志, 2024, 57(4): 374-378.
[8]	宋雨晴杨楠刘琳琳冯子仪韩世新周梅娟. [开放获取] 皮肤磨削术治疗家族性良性慢性天疱疮6例临床观察[J]. 中华皮肤科杂志, 2024, 0(4): 20220278-e20220278.
[9]	葛新红马迎东焦亚宁刘玲玲周镁紫薇李博文. 532 nm皮秒激光治疗面部早期脂溢性角化病的疗效和安全性分析[J]. 中华皮肤科杂志, 2024, 57(4): 359-362.
[10]	岳淑珍树叶罗鸯鸯李珂瑶张圆圆汤建萍韦祝. 奥马珠单抗治疗儿童慢性荨麻疹的疗效和安全性回顾研究[J]. 中华皮肤科杂志, 2024, 57(4): 354-358.
[11]	刘祎曲莹雷文知刘晓刚潘炜华张超. 食盐封包法治疗化脓性肉芽肿25例临床观察[J]. 中华皮肤科杂志, 2024, 0(4): 20230553-e20230553.
[12]	鞠强李嘉祺. [开放获取] 寻常痤疮再认识：从发病机制到治疗策略[J]. 中华皮肤科杂志, 2024, 57(4): 289-294.
[13]	张迪敏曹成周妙妮盛安琪林福全许爱娥. 复方倍他米松注射液联合治疗后进展期非节段型白癜风稳定率及影响因素分析[J]. 中华皮肤科杂志, 2024, 57(4): 350-354.
[14]	田静邓思思宋志强. 特应性与非特应性结节性痒疹患者临床特征比较[J]. 中华皮肤科杂志, 2024, 57(4): 331-337.
[15]	严可心张韡宋昊徐秀莲. 纳米医学在恶性黑色素瘤中的诊断和治疗新策略[J]. 中华皮肤科杂志, 2024, 0(3): 20230109-e20230109.

遗传性血管性水肿治疗方式与疾病负担研究进展

Treatment and disease burden of hereditary angioedema

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 47

相关文章 15

Metrics

本文评价

推荐阅读 10